Datapoint: Alvotech Aims to Get Humira Biosimilar to Market Sooner With Lawsuit

Though Humira biosimilars are set to launch in the U.S. in 2023, biopharmaceutical manufacturer Alvotech is aiming to get its biosim, AVT02, to market faster via a federal lawsuit, per a May 11 press release. Alvotech says AbbVie engaged in “inequitable conduct” to gain its Humira patents, among other allegations centered around the drugmaker’s attempt to “overwhelm” the company with legal issues and create a “wrongful monopoly.” For the treatment of rheumatoid arthritis, the Humira pen holds covered or better status for 70% of all insured lives under the pharmacy benefit. It is classified as a specialty drug for 29.8% of covered lives.

SOURCE: MMIT Analytics, as of 5/12/21

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 22

Datapoint: CMS Extends Medicaid Redetermination Deadline

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 21

Datapoint: Aetna Shut Out of Medicaid Contract Awards

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 20

Datapoint: FDA Expands Otezla’s Psoriasis Label

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today